Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide once-weekly versus placebo for gastric emptying in type 2 diabetes
ACTRN12619000497101Phase 2Completed
- Sponsor
- University of Adelaide
- Start
- Jan 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Exenatide once weekly with Matching placebo once weekly (2 arms). Primary endpoint: Change in gastric emptying after 8 weeks. Started Jan 2020; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12619000497101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000497101.